Professor, Internal Medicine, University of Texas Medical Branch SOM
Cardiology
Dr. Kenichi Fujise, MD
|
|
Give Review
Dr. Kenichi Fujise works in the field of Cardiology. He researched medicine at New York Medical College - Metropolitan Hospital Center. He received 1 awards: "CMS Meaningful Use Stage 1 Certification". Doctor Kenichi Fujise, MD is a published doctor and has 48 publications published. The lastest was: 'Bubble at tip of the stent delivery system of the Palmaz-Schatz stent improves trackability to the target site.' Kenichi Fujise is registered with Medicare.
Publications
- Influence of Access, Anticoagulant, and Bleeding Definition on Outcomes of Primary Percutaneous Coronary Intervention: Early Experience of an US Academic Center.
- Severe cardiovascular changes associated with pancuronium after cardioPulmonary resuscitation and after brain injury.
- [Combination therapy of hyperthermia and other methods in liver and bile tract cancers--evaluation of these methods using cancer cell lines in vitro].
- [AntiHypertensive effect of nasal nifedipine and its plasma concentration during anesthesia and surgery].
- [Establishment and characterization of human pancreatic adenocarcinoma cell line JHP-1 producing carbohydrate antigen 19-9 and carcinoembryonic antigen].
- Images in clinical medicine. Coronary arteriovenous fistula on Coronary angiography.
- [A case of B-cell non-Hodgkin''s lymphoma with prominent splenomegaly and high serum titer of cold agglutinin].
- A tissue plasminogen activator/P-selectin fusion protein is an effective thrombolytic agent.
- Causes of early reintervention after successful Coronary artery stenting.
- Timing of Coronary stent thrombosis in patients treated with prophylactic tirofiban.
- Percutaneous intervention in saphenous venous grafts: in-stent restenosis lesions are safer than de novo lesions.
- Bubble at tip of the stent delivery system of the Palmaz-Schatz stent improves trackability to the target site.
- Adenosine use during aortoCoronary vein graft interventions reverses but does not prevent the slow-no reflow phenomenon.
- Risk assessment of slow or no-reflow phenomenon in aortoCoronary vein graft percutaneous intervention.
- Preferential interaction of sentrin with a ubiquitin-conjugating enzyme, Ubc9.
- Differential effects of endothelin receptor activation on cyclic flow variations in rat mesenteric arteries.
- Infrapopliteal transcatheter interventions for limb salvage in diabetic patients: importance of aggressive interventional approach and role of transcutaneous oximetry.
- Effects of clopidogrel pretreatment before percutaneous Coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban).
- Intracoronary adenosine administered during percutaneous intervention in Acute myocardial infarction and reduction in the incidence of "no reflow" phenomenon.
- IntraCoronary adenosine administered during rotational atherectomy of complex lesions in native Coronary arteries reduces the incidence of no-reflow phenomenon.
- Regulation of apoptosis and cell cycle progression by MCL1. Differential role of proliferating cell nuclear antigen.
- Characterization of fortilin, a novel antiapoptotic protein.
- Identification and characterization of syntenin binding protein in the black tiger shrimp Penaeus monodon.
- Vascular access site complications with the use of closure devices in patients treated with platelet glycoprotein IIb/IIIa inhibitors during rescue angioplasty.
- Cardiac calcitonin gene-related peptide and left ventricular hypertrophy in the cardiac allograft.
- Reducing ischaemia/reperfusion injury through delta-opioid-regulated intrinsic cardiac adrenergic cells: adrenopeptidergic co-signalling.
- Pre-hospital reduced-dose fibrinolysis coupled with urgent percutaneous Coronary intervention reduces time to reperfusion and improves angiographic perfusion score com...
- Delta-opioid augments cardiac contraction through ?-adrenergic and CGRP-receptor co-signaling.
- Heart protection by combination therapy with esmolol and milrinone at late-ischemia and early reperfusion.
- Cardiac allograft vasculopathy: advances in diagnosis.
- Morelloflavone from Garcinia dulcis as a novel biflavonoid inhibitor of HMG-CoA reductase.
- Morelloflavone, a biflavonoid inhibitor of migration-related kinases, ameliorates atherosclerosis in mice.
- Human papillomavirus and cardiovascular Disease among U.S. women in the National Health and Nutrition Examination Survey, 2003 to 2006.
- Physical and functional antagonism between tumor suppressor protein p53 and fortilin, an anti-apoptotic protein.
- Fortilin binds Ca2+ and blocks Ca2+-dependent apoptosis in vivo.
- Management of hypertension in chronic Heart failure.
- Embryonic lethality of fortilin-null mutant mice by BMP-pathway overactivation.
- Morelloflavone, a biflavonoid, inhibits tumor angiogenesis by targeting rho GTPases and extracellular signal-regulated kinase signaling pathways.
- Morelloflavone blocks injury-induced neointimal formation by inhibiting vascular smooth muscle cell migration.
- The critical role of the intrinsic VSMC proliferation and death programs in injury-induced neointimal hyperplasia.
- Human fortilin is a molecular target of dihydroartemisinin.
- Antiapoptotic protein partners fortilin and MCL1 independently protect cells from 5-fluorouracil-induced cytotoxicity.
- Profound negative regulatory effects by resveratrol on vascular smooth muscle cells: a role of p53-p21(WAF1/CIP1) pathway.
- Paradoxical upregulation of tumor suppressor protein p53 in serum-stimulated vascular smooth muscle cells: a novel negative-feedback regulatory mechanism.
- Adenoviral gene transfer of fortilin attenuates neointima formation through suppression of vascular smooth muscle cell proliferation and migration.
- Outcome of access site in patients treated with platelet glycoprotein IIb/IIIa inhibitors in the era of closure devices.
- Physical and functional interaction between myeloid cell leukemia 1 protein (MCL1) and Fortilin. The potential role of MCL1 as a fortilin chaperone.
Schools
Kyoto University Faculty Of Medicine
Metro Hospital Center
Beth Israel Med Center
University Tex Health Science Center
Procedures Preformed
- Cardiac Catheterization (incl. Coronary Angiography)
- Cardiac Imaging
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Cardiac Myocardial Perfusion Imaging
- View All
Conditions Treated
- Aneurysm and Dissection of Heart
- Angina and Acute Coronary Syndrome
- Aortic Aneurysm
- Aortic Dissection
- View All
Doctors Specialties
- Cardiology
- Interventional Cardiology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Mount Sinai Beth Israel -
New York Medical College - Metropolitan Hospital Center -
Faculty of Medicine Kyoto University
Hospital
-
Mainland Medical Center
Drug Facts
| NPI NUMBER | 1861426009 | |
| NPPES Provider LastName | FUJISE | |
| NPPES Provider FirstName | KENICHI | |
| NPPES Provider ZIPCode | 770303000 | |
| NPPES Provider State | TX | |
| Specialty Description | Cardiology | |
| Total Claim Count | 692.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1861426009 |
| Last Name Of The Provider | FUJISE |
| First Name Of The Provider | KENICHI |
| View All |